Business
Lantern Pharma Announces Abstract on Effectiveness of LP-184 in Glioblastoma Accepted for Presentation at the Society for Neuro-Oncology 2021 Annual Meeting
DALLAS, Nov. 11, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial
About this update from Lantern Pharma Inc.
[{"type":"text","content":"DALLAS, Nov. 11, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (\"A.I.\") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that Lantern Pharma's abstract on the effectiveness of LP-184 in glioblastoma multiforme (GBM) regardless of MGMT status has been accepted as a virtual poster at the upcoming 26th Society for Neuro-Oncology (SNO) Annual Meeting, which is being held in person and virtually from November 18-21, 2021. The abstract is available online on the SNO website.\n\n \n \n \n \n \n \n\n \nAbstract Title: LP-184, a novel alkylating agent, is effective in GlioblastomaAbstract ID: EXTH-16 Submission type: AdultAbstract Tumor Type: Glial TumorsAbstract Category: Preclinical Experimental TherapeuticsPoster Session Date & Time: Friday, November 19, 2021, 7:30 PM - 9.30 PM ESTPresenter: Aditya Kulkarni, Ph.D., Lantern Pharma\nThe abstract submitted by Lantern Pharma and researchers at The Kennedy Krieger Institute affiliated with Johns Hopkins School of Medicine describes work demonstrating promising efficacy of LP-184 in multiple in vitro and in vivo glioblastoma models. The abstract also highlights the increased efficacy of LP-184 in MGMT unmethylated GBM, an area of large unmet clinical need, as well as the predicted synthetic lethality of LP-184 in GBM with DNA damage repair deficiencies such as decreased expression of nucleotide excision repair components ERCC3/6. The poster displays the favorable blood brain barrier crossing properties of LP-184 evaluated in vivo, suggesting that the maximum brain concentration achieved after a single intravenous infusion of LP-184 in mice is greater than that required for growth inhibition of sensitive GBM cells. These findings identify LP-184 as a promising new alkylating agent and support its further development for GBM therapy.\nElectronic poster presentation files will be captured electronically (in PDF) prior to the meeting and available on the mobile meeting app, website and onsite. Accepted abstracts will be published as a proceedings supplement in Neuro-Oncology, the official journal of the SNO after the completion of the meeting.\nLP-184 is a small molecule drug candidate and next generation acylfulvene that preferenti...